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Regarding ‘Early postoperative
serum cystatin C predicts severe
acute kidney injury following
pediatric cardiac surgery’
To the Editor: We read with interest the recent article by
Zappitelli et al.1 We have three remarks to press on.
The classiﬁcation in mild and severe acute kidney injury
(AKI) as described on page 661 does not correspond to the
one by the Acute Kidney Injury Network. In fact, need for
dialysis should be classiﬁed as stage 3. Furthermore, both the
proposed stages include ‘need for dialysis’ as a condition,
which puzzled us a bit.
We are also confused by the use for different variables of
quintiles or tertiles: why not to use only quintiles?
However, the more important fact, it seems to us, is the
problem of whether all the cystatin C values contained
in the 5th or 3rd percentiles are a true expression of a
deranged renal function rather than that of analytical
imprecision. Using the available data on biological varia-
bility2,3 and an estimated laboratory analytical coefﬁcient
of variation of 4.5% (as the authors do not report their
own one), the calculated reference change value4 for
cystatin C is around 25%. This means that in a single indi-
vidual, only a cystatin change 425% between two measure-
ments can detect a signiﬁcant change in his/her renal
function. Hence, the questions are ‘How many patients in
the 5th and 3rd percentiles for predicting AKI fall below
the reference change value?’ and ‘With this limitation, is
early postoperative cystatin C still effective in predicting
severe AKI?’
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The Authors Reply: We thank Gambaro et al.1 for
their letter. Below are the clarifications for the three
questions raised. First, our outcomes were ‘mild’ or stage
1 acute kidney injury (AKI) or worse (including higher
AKI stages and dialysis) and ‘severe’ or stage 2 AKI
or worse (including stage 3 and dialysis). Dialysis
was correctly included in both the AKI definitions to
assure that patients receiving dialysis, but not fulfilling
serum creatinine (SCr) criteria, were categorized as having
AKI.2 Second, they queried our use of quintiles to
evaluate cystatin C (CysC) values (mg/dl) vs. tertiles to
evaluate % CysC change. We would have preferred
quintiles (more granularity) for all analyses but event rates
within quintile groups were very low for stage 2 AKI,
limiting us to analysis of tertiles. Finally, they note the
issue of CysC biological variability. Although contro-
versial,3 CysC may have higher intraindividual variation
than SCr.4 CysC measurement imprecision can contribute
to subject misclassification in given percentile groups;
we measured all samples in a single batch in a CLIA-
approved clinical laboratory, which would reduce mea-
surement variation. We reported our coefficient of
variation for CysC measurement as 1.1% (page 660).2
Importantly, such misclassification and increased vari-
ability would lead to decreased likelihood of finding
an association with the study outcome. In addition,
the third tertile of % CysC change was composed of
patients with 4 to 143% CysC change from baseline
(Table 3).2 The association with AKI should only get
stronger if we eliminated patients in the lower end (o25%
CysC change).
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CKD-associated atherosclerosis
and monocyte heterogeneity
To the Editor:We noticed with great interest the mini review
‘Novel inﬂammatory mechanisms of accelerated atherosclero-
sis in kidney disease’ by Swaminathan and Shah.1
Although we commend the authors for their efforts to
highlight the substantial impact of monocyte heterogeneity
in chronic kidney disease-associated atherosclerosis, we are
surprised that the authors exclusively relied on data obtained
from murine experiments, ignoring the limits of homology
between murine and human monocyte heterogeneity.
Notably, in mice, Gr1þ /Ly6Chigh monocytes (the putative
homologs of human CD14þþCD16 monocytes) are proin-
ﬂammatory, and they are more prone to enter the athero-
sclerotic plaque than Gr1/Ly6Clow monocytes.1 In contrast,
in humans, CD16-positive monocytes (CD14þþCD16þ and
CD14þCD16þþ cells, which are counterparts of murine
Gr1/Ly6Clow monocytes) are considered proinﬂammatory
cells by most groups (as reviewed in Ziegler-Heitbrock2).
Moreover, ample circumstantial evidence (as discussed in
Rogacev et al.3) and clinical data demonstrate that
CD14þþCD16þ monocytes3,4—but not CD14þþCD16
monocytes—are the relevant monocytes in human athero-
sclerosis. The importance of the CD14þþCD16þ monocyte
subsets in nephrology is underscored by the profoundly
elevated counts of these cells in dialysis patients4 and their
activation during dialysis (referenced in Rogacev et al.3).
Taken together, we agree with the authors that knowledge
of monocyte heterogeneity is of major relevance to both
clinicians and researchers in nephrology. We kindly disagree
with the uncritical transfer of murine data to human
(patho)physiology.
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The Authors Reply: We thank Rogacev et al.1 for their
interest in our mini review ‘Novel Inflammatory Mechanisms
of Accelerated Atherosclerosis in Kidney Disease.’2 While we
appreciate and acknowledge the important points raised by
the authors regarding homology of monocyte heterogeneity
between mice and humans, we suggest several additional
aspects that are worth considering.
Although we agree that Gr1þ /Ly6Chi are pro-inﬂamma-
tory monocytes and are putative homologs of human
CD14þCD16 monocytes, in many settings, depending on
local and systemic cues, they can also differentiate into a
variety of macrophage and dendritic cell (DC) subtypes that
could inhibit immune response.3
Pertaining to atherosclerosis, although Ly6Chi monocytes
more efﬁciently accumulate in atherosclerotic plaques, Ly6Clo
anti-inﬂammatory monocytes were particularly prone to
developing into plaque cells that express the DC marker
CD11c.4 Similarly, in human atheroma, macrophages express
c-fms (macrophage colony-stimulating factor receptor) but
not inﬂammatory cytokines such as interleukin-6,5and
CD14þCD16 rather than CD16þ monocytes correlate with
worse myocardial salvage after myocardial infarction.6
More recently, gene expression proﬁling has identiﬁed
close similarities between murine and human monocyte
subsets in more than 100 genes, suggesting similarity between
Ly6Chi monocytes and human CD14þCD16 monocytes,
and between Ly6Clo anti-inﬂammatory mouse monocytes
and CD16þ human monocytes.7 This has led the authors to
refer to monocytes as CD14þCD16 and CD16þ subsets in
both species. However, it is important to point out some
notable differences that the authors observed between the
homologous human and mouse monocyte subsets, especially
in PPAR-g and phagocytic receptor expression.
Thus, origin, differentiation, and plasticity of different
monocyte subsets in mice, and the corresponding cell
populations in humans and their independent role in health
and disease, remain to be fully elucidated.
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